Alimera Sciences, Inc. (NASDAQ:ALIM) CEO C. Daniel Myers sold 52,900 shares of the firm’s stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $1.20, for a total transaction of $63,480.00. Following the sale, the chief executive officer now owns 101,511 shares of the company’s stock, valued at approximately $121,813.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
C. Daniel Myers also recently made the following trade(s):
- On Wednesday, January 17th, C. Daniel Myers sold 52,900 shares of Alimera Sciences stock. The stock was sold at an average price of $1.23, for a total transaction of $65,067.00.
Alimera Sciences, Inc. (ALIM) traded down $0.04 on Friday, hitting $1.20. 328,891 shares of the stock traded hands, compared to its average volume of 129,121. The stock has a market capitalization of $85.74, a P/E ratio of -3.87 and a beta of 2.16. The company has a debt-to-equity ratio of -0.71, a current ratio of 4.84 and a quick ratio of 4.65. Alimera Sciences, Inc. has a 52-week low of $1.11 and a 52-week high of $1.72.
Several equities analysts have recently weighed in on the stock. ValuEngine downgraded shares of Alimera Sciences from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 3rd. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Alimera Sciences in a research note on Wednesday, November 22nd. Zacks Investment Research upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Monday, January 8th. Finally, Cowen reiterated a “buy” rating on shares of Alimera Sciences in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $3.38.
An institutional investor recently raised its position in Alimera Sciences stock. Stonepine Capital Management LLC raised its holdings in Alimera Sciences, Inc. (NASDAQ:ALIM) by 158.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 477,226 shares of the biopharmaceutical company’s stock after purchasing an additional 292,399 shares during the period. Alimera Sciences accounts for about 0.4% of Stonepine Capital Management LLC’s holdings, making the stock its 21st biggest position. Stonepine Capital Management LLC owned 0.69% of Alimera Sciences worth $644,000 at the end of the most recent quarter. Institutional investors own 41.78% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Alimera Sciences, Inc. (ALIM) CEO Sells $63,480.00 in Stock” was originally reported by BBNS and is the property of of BBNS. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://baseballnewssource.com/markets/alimera-sciences-inc-alim-ceo-sells-63480-00-in-stock/1848558.html.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.